Lou Gehrig's Disease or Amyotrophic Lateral Sclerosis (ALS) is a neurological disorder characterized by progressive degeneration of motor neuron cells in the spinal cord and brain, which ultimately results in paralysis and death. The disease takes its less-scientific name from Lou Gehrig, a baseball player with the New York Yankees in the late 1920s and 1930s, who was forced to retire in 1939 as a result of the loss of motor control caused by the disease.
In 1991, a team of researchers linked familial ALS to chromosome 21. Two years later, the SOD1 gene was identified as being associated with many cases of familial ALS. The enzyme coded for by SOD1 carries out a very important function in cells: it removes dangerous superoxide radicals by converting them into non-harmful substances. Defects in the action of this enzyme mean that the superoxide radicals attack cells from the inside, causing their death. Several different mutations in this enzyme all result in ALS, making the exact molecular cause of the disease difficult to ascertain.
Recent research has suggested that treatment with drugs called antioxidants may benefit ALS patients. However, since the molecular genetics of the disease are still unclear, a significant amount of research is still required to design other promising treatments for ALS.
Treatment with dexpramipexole - a novel drug believed to prevent dysfunction of mitochondria, the subcellular structures that provide most of a cell's energy - appears to slow symptom progression in the neurodegenerative disease amyotrophic lateral sclerosis (ALS). Promising results of a phase 2 trial of dexpramipexole are receiving advance online publication in Nature Medicine.
Amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, is a universally fatal neurodegenerative disease. Mutations in two related proteins, TDP-43 and FUS, cause some forms of ALS. Specifically, these two proteins are RNA-binding proteins that connect to RNA to regulate the translation of proteins and other cellular functions such as RNA splicing and editing. In a new study, researchers at the Perelman School of Medicine at the University of Pennsylvania discovered additional human genes with properties similar to TDP-43 and FUS that might also contribute to ALS.
Two proteins conspire to promote a lethal neurological disease, according to a study published online this week in the Journal of Experimental Medicine.
Current thinking about Parkinson's disease is that it's a disorder of mitochondria, the energy-producing organelles inside cells, causing neurons in the brain's substantia nigra to die or become impaired.
U.S. researchers have finally found a way to overcome difficulties in coaxing human embryonic stem cells to become the neurons killed by Parkinson's disease.
Avanir Pharmaceuticals, Inc. announced today that it has submitted an application to the European Medicines Agency seeking marketing authorization for NUEDEXTA (dextromethorphan HBr and quinidine sulfate) for the treatment of pseudobulbar affect.
Neuralstem, Inc. updated the progress of its ongoing Phase I safety trial of the company's spinal cord stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) at Emory University in Atlanta, Georgia.
Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that its planned clinical trial of the Company's proprietary zinc-based therapy for patients suffering from amyotrophic lateral sclerosis, also known as Lou Gehrig's Disease, will be featured during the Hot Topics session at the 2011 California ALS Research Summit on Saturday, October 1, 2011.
An electronic system that stimulates the nerve of the diaphragm muscles has received approval from the Food and Drug Administration (FDA) for use in patients with Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease.
Researchers at the University of Missouri have identified a communication breakdown between nerves and muscles in mice that may provide new insight into the debilitating and fatal human disease known as spinal muscular atrophy.
Frontotemporal dementia and amyotrophic lateral sclerosis, also known as Lou Gehrig's disease -- two fatal neurodegenerative disease with distinct but sometimes overlapping symptoms -- are triggered by a common mutation in many cases, according to researchers who say they have identified the mutated gene.
A team led by scientists from Johns Hopkins and the National Institutes of Health has discovered a new genetic mutation for amyotrophic lateral sclerosis (ALS) and a related disease called frontotemporal dementia (FTD) that appears to account for more than a third of all inherited cases of these diseases.
The ability to produce neuroprotectors, proteins that protect the human brain against neurodegenerative disorders such as Parkinson's and ALS, is the holy grail of brain research. A technology developed at Tel Aviv University does just that, and it's now out of the lab and in hospitals to begin clinical trials with patients suffering from amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.
A team of researchers from the University of British Columbia and the Vancouver Coastal Health Research Institute have found a key link between prions and the neurodegenerative disease ALS (Amyotrophic Lateral Sclerosis), also known as Lou Gehrig’s disease. The discovery is significant as it opens the door to novel approaches to the treatment of ALS.
Mayo Clinic's campus in Florida has entered into a collaborative and sponsored research agreement with SK Biopharmaceuticals of Seoul, South Korea, with the goal of developing new treatments for amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease. The collaboration marks a new approach to combating a disease that has proved difficult to treat in recent clinical trials.
South Korean biotech SK biopharmaceuticals announced yesterday that they signed an agreement to collaborate with the Mayo Clinic for the discovery of new drugs targeting Amyotrophic Lateral Sclerosis.
Recently published studies by a researcher in the Faculty of Medicine & Dentistry demonstrate that ALS - known as Lou Gehrig's disease - damages neurons in parts of the brain responsible for cognition and behaviour.
A group led by a University of British Columbia and Vancouver Coastal Health scientist has discovered a type of spinal cord cell that could function as a stem cell, with the ability to regenerate portions of the central nervous system in people with spinal cord injuries, multiple sclerosis or amyotrophic lateral sclerosis.
The Allen Institute for Brain Science announced today the discovery of a new class of cells in the spinal cord that act like neural stem cells, offering a fresh avenue in the search for therapies to treat spinal cord injury and disease.
Nobody likes to get stuck with a needle. But influenza - the flu - is particularly hazardous for those with neuromuscular disease, which is why the Muscular Dystrophy Association (MDA) and Walgreens have teamed up once again to offer free seasonal flu shots now underway for people who have muscular dystrophy and related diseases.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.